Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Pb Multiple | -0.3x - -0.3x | -0.3x |
| Historical Pb Multiple | -2.3x - 5.1x | -0.3x |
| Fair Value | $0.46 - $0.51 | $0.48 |
| Upside | -54.1% - -49.2% | -51.7% |
| Benchmarks | - | Full Ticker |
| Dyadic International, Inc. | - | NasdaqCM:DYAI |
| Onconetix, Inc. | - | NasdaqCM:ONCO |
| Cardiff Oncology, Inc. | - | NasdaqCM:CRDF |
| Geron Corporation | - | NasdaqGS:GERN |
| Trevena, Inc. | - | OTCPK:TRVN |
| Vaccinex, Inc. | - | OTCPK:VCNX |
| Select Price / Book Ratio | ||||||||
| Benchmark Companies | ||||||||
| DYAI | ONCO | CRDF | GERN | TRVN | VCNX | |||
| NasdaqCM:DYAI | NasdaqCM:ONCO | NasdaqCM:CRDF | NasdaqGS:GERN | OTCPK:TRVN | OTCPK:VCNX | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| Latest Twelve Months | 28.0% | 16.4% | -24.9% | 59.9% | -10.6% | 8.0% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -369.0% | -12137.7% | -7820.9% | -22205.7% | -19680.3% | -9907.1% | ||
| Prior Fiscal Year | -234.4% | -63986.5% | -8496.9% | -77690.7% | 12839.7% | -3552.8% | ||
| Latest Fiscal Year | -166.2% | -2333.4% | -6655.2% | -226.7% | -1289.2% | -3100.5% | ||
| Latest Twelve Months | -134.8% | -3345.3% | -9365.7% | -53.5% | -6233.7% | -3100.5% | ||
| Return on Equity | ||||||||
| 5 Year Average Margin | -90.4% | -450.2% | -46.8% | -69.8% | -273.1% | -943.0% | ||
| Prior Fiscal Year | -80.1% | -334.2% | -47.1% | -112.3% | -133.8% | -779.9% | ||
| Latest Twelve Months | -352.0% | -1502.3% | -92.0% | -31.1% | -1918.1% | NM | ||
| Next Fiscal Year | 814.0% | 222.3% | -103.0% | -35.0% | 112.4% | 241.9% | ||
| Two Fiscal Years Forward | 78.6% | 80.6% | 1098.6% | -13.9% | 17.5% | 139.6% | ||
| Current Trading Multiples | ||||||||
| Price / LTM Sales | 7.4x | 3.5x | 283.2x | 5.7x | 0.5x | 2.3x | ||
| Price / LTM EPS | -5.5x | -0.1x | -3.0x | -10.6x | 0.0x | -0.1x | ||
| Price / Book | -58.1x | 0.8x | 2.6x | 3.6x | 0.0x | -0.3x | ||
| Price / Fwd Book | -7.5x | 0.0x | 5.8x | 4.7x | 0.0x | 0.1x | ||
| Low | Mid | High | ||||||
| Benchmark P/B Ratio | -58.1x | 0.8x | 3.6x | |||||
| Historical P/B Ratio | -2.3x | -0.3x | 5.1x | |||||
| Selected P/B Multiple | -0.3x | -0.3x | -0.3x | |||||
| (x) Book Value | (4) | (4) | (4) | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | DYAI | ONCO | CRDF | GERN | TRVN | VCNX | |
| Value of Common Equity | 31 | 5 | 154 | 932 | 0 | 3 | |
| (/) Shares Outstanding | 36.2 | 1.5 | 66.5 | 638.0 | 1.0 | 2.7 | |
| Implied Stock Price | 0.85 | 2.97 | 2.32 | 1.46 | 0.28 | 1.00 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 0.85 | 2.97 | 2.32 | 1.46 | 0.28 | 1.00 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |